Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Account Payables (2023 - 2025)

Neurogene (NGNE) has disclosed Change in Account Payables for 2 consecutive years, with -$501000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 1627.59% year-over-year to -$501000.0, compared with a TTM value of -$198000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of -$77000.0, down 111.54% over the prior year.
  • Change in Account Payables was -$501000.0 for Q3 2025 at Neurogene, up from -$975000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.7 million in Q1 2025 and bottomed at -$975000.0 in Q2 2025.